亚虹医药：子公司产品APL - 2401获澳大利亚Ⅰ期临床许可

Core Viewpoint - Asieris Pharmaceuticals has received approval from Australian authorities to conduct Phase I clinical trials for its product APL-2401, a dual-target small molecule inhibitor for FGFR2/3, which is expected to provide a new treatment option for patients with advanced solid tumors [1] Group 1 - APL-2401, also known as ASN-8639 tablets, has been developed independently by the company [1] - The product has previously received clinical trial approval from the National Medical Products Administration [1] - The approval in Australia is not expected to have a significant impact on the company's recent performance, and there are uncertainties associated with the research and development process [1]